Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-10-28 Sale | 2024-10-30 7:30 pm | Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO | 25,000 | $53.54 | $1,338,559 | 282,054 (Direct) | View |
| 2024-09-13 Sale | 2024-10-24 4:15 pm | Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner | 3,815 | $46.68 | $178,084 | 6,618,252 (Indirect Direct) | View |
| 2024-10-18 Purchase | 2024-10-22 4:20 pm | Janux Therapeutics Inc. | JANX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 1,200,000 | $44.75 | $53,700,000 | 10,365,652 (Indirect) | View |
| 2024-10-16 Sale | 2024-10-18 6:51 pm | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 1,673,128 | $46.3 | $77,472,371 | 4,281,533 (Indirect Direct) | View |
| 2024-09-26 Sale | 2024-09-30 8:49 pm | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 307,779 | $46.96 | $14,452,394 | 3,005,777 (Indirect Direct) | View |
| 2024-09-27 Sale | 2024-09-27 7:32 pm | Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer | 50,000 | $45.96 | $2,297,755 | 168,259 (Direct) | View |
| 2024-09-27 Sale | 2024-09-27 7:31 pm | Janux Therapeutics Inc. | JANX | DiRaimondo Thomas Chief Scientific Officer | 5,000 | $46.34 | $231,716 | 97,938 (Direct) | View |
| 2024-09-27 Sale | 2024-09-27 7:30 pm | Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO | 25,000 | $46.31 | $1,157,641 | 307,054 (Direct) | View |
| 2024-09-10 Sale | 2024-09-12 8:42 pm | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 451,091 | $46.89 | $21,153,619 | 5,987,589 (Indirect Direct) | View |
| 2024-09-06 Sale | 2024-09-10 5:02 pm | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 242,182 | $42 | $10,172,364 | 3,297,625 (Indirect Direct) | View |
| 2024-06-03 Sale | 2024-06-05 7:25 pm | Janux Therapeutics Inc. | JANX | Lichter Jay Director 10% Owner | 1,500,000 | $54.75 | $82,125,000 | 3,344,601 (Indirect Direct) | View |
| 2024-06-03 Sale | 2024-06-05 7:23 pm | Janux Therapeutics Inc. | JANX | Reardon Tighe Acting Chief Financial Officer | 822,721 | $54.75 | $45,043,975 | 3,515,007 (Indirect Direct) | View |
| 2024-06-03 Sale | 2024-06-05 7:19 pm | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. 10% Owner | 1,500,000 | $54.75 | $82,125,000 | 6,611,234 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-11-05 Other | 2024-11-07 7:09 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Gujrathi Sheila Director | 4,611 | $0 | 119,750 (Direct) | View |
| 2024-11-05 Other | 2024-11-07 7:08 pm | N/A N/A | Janux Therapeutics Inc. | JANX | CAPPS VICKIE L Director | 2,305 | $0 | 72,653 (Direct) | View |
| 2024-09-13 Exercise | 2024-10-24 4:15 pm | N/A 2027-07-19 | Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner | 3,815 | $0 | 6,618,252 (Direct) | View |
| 2024-09-13 Exercise | 2024-10-24 4:15 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner | 391 | $39.8 | 6,618,252 (Direct) | View |
| 2024-09-13 Exercise | 2024-10-24 4:15 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner | 778 | $10.73 | 6,618,252 (Direct) | View |
| 2024-09-13 Exercise | 2024-10-24 4:15 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner | 1,868 | $17 | 6,618,252 (Direct) | View |
| 2024-09-13 Exercise | 2024-10-24 4:15 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Lichter Jay 10% Owner | 778 | $13.22 | 6,618,252 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-18 6:51 pm | N/A 2027-07-19 | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 12,284 | $0 | 4,281,533 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-18 6:51 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 1,644 | $39.8 | 4,281,533 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-18 6:51 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 2,418 | $10.73 | 4,281,533 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-18 6:51 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 5,804 | $17 | 4,281,533 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-18 6:51 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 2,418 | $13.22 | 4,281,533 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-30 8:49 pm | N/A 2027-07-19 | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 2,671 | $0 | 3,005,777 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-30 8:49 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 357 | $39.8 | 3,005,777 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-30 8:49 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 526 | $10.73 | 3,005,777 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-30 8:49 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 1,262 | $17 | 3,005,777 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-30 8:49 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 526 | $13.22 | 3,005,777 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-27 7:32 pm | N/A 2031-03-09 | Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer | 50,000 | $0 | 168,259 (Direct) | View |
| 2024-09-27 Exercise | 2024-09-27 7:32 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer | 50,000 | $4.21 | 168,259 (Direct) | View |
| 2024-09-09 Exercise | 2024-09-10 5:02 pm | N/A 2027-07-19 | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 2,099 | $0 | 3,297,625 (Direct) | View |
| 2024-09-09 Exercise | 2024-09-10 5:02 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 277 | $39.8 | 3,297,625 (Direct) | View |
| 2024-09-09 Exercise | 2024-09-10 5:02 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 414 | $10.73 | 3,297,625 (Direct) | View |
| 2024-09-09 Exercise | 2024-09-10 5:02 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 994 | $17 | 3,297,625 (Direct) | View |
| 2024-09-09 Exercise | 2024-09-10 5:02 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures I LP Avalon BioVentures SPV I L.P. Lichter Jay 10% Owner | 414 | $13.22 | 3,297,625 (Direct) | View |
Ownership | 2024-08-09 7:06 pm | N/A 2031-03-09 | Janux Therapeutics Inc. | JANX | Dobek Maria Vice President, Accounting | 0 | $0 | 73,698 (Direct) | View |
| 2024-07-19 Option Award(A) | 2024-07-24 8:00 pm | N/A 2034-07-18 | Janux Therapeutics Inc. | JANX | DOBMEIER ERIC Director | 5,342 | $0 | 10,342 (Direct) | View |
| 2024-07-19 Option Award(A) | 2024-07-24 8:00 pm | N/A 2034-07-18 | Janux Therapeutics Inc. | JANX | Hernday Natasha Director | 5,342 | $0 | 10,342 (Direct) | View |
| 2024-07-19 Option Award | 2024-07-22 8:04 pm | N/A 2034-07-18 | Janux Therapeutics Inc. | JANX | DOBMEIER ERIC Director | 32,550 | $0 | 32,550 (Direct) | View |
| 2024-07-19 Option Award | 2024-07-22 8:03 pm | N/A 2034-07-18 | Janux Therapeutics Inc. | JANX | Hernday Natasha Director | 32,550 | $0 | 32,550 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:35 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. Director 10% Owner | 10,850 | $0 | 9,176,502 (Indirect) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | Lichter Jay Director 10% Owner | 10,850 | $0 | 7,260,340 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | McNulty Alana B. Director | 10,850 | $0 | 10,850 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | Kung Winston Director | 10,850 | $0 | 10,850 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | Gujrathi Sheila Director | 10,850 | $0 | 118,878 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | Barrett Ronald W Director | 10,850 | $0 | 10,850 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | Simson Jake Director | 10,850 | $0 | 10,850 (Direct) | View |
| 2024-06-26 Option Award | 2024-06-28 4:30 pm | N/A 2034-06-25 | Janux Therapeutics Inc. | JANX | CAPPS VICKIE L Director | 10,850 | $0 | 76,393 (Direct) | View |
| 2024-02-29 Other | 2024-03-04 7:31 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Avalon Ventures XI L.P. Avalon BioVentures SPV I L.P. Avalon BioVentures I LP 10% Owner | 1,016,200 | $0 | 5,009,239 (Direct) | View |
| 2024-02-29 Other | 2024-03-04 4:44 pm | N/A N/A | Janux Therapeutics Inc. | JANX | Gujrathi Sheila Director | 2,986 | $0 | 111,014 (Direct) | View |
| 2024-02-29 Other | 2024-03-04 4:33 pm | N/A N/A | Janux Therapeutics Inc. | JANX | CAPPS VICKIE L Director | 1,493 | $0 | 67,036 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-03 4:54 pm | N/A 2034-01-01 | Janux Therapeutics Inc. | JANX | Winter Charles M. Chief Technical Officer | 111,000 | $0 | 111,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-03 4:53 pm | N/A 2034-01-01 | Janux Therapeutics Inc. | JANX | Robinson Byron Chief Strategy Officer | 151,500 | $0 | 151,500 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-03 4:52 pm | N/A 2034-01-01 | Janux Therapeutics Inc. | JANX | Reardon Tighe Acting Chief Financial Officer 10% Owner | 157,000 | $0 | 157,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-03 4:50 pm | N/A 2034-01-01 | Janux Therapeutics Inc. | JANX | Meyer Andrew Hollman Chief Business Officer | 105,000 | $0 | 105,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-03 4:49 pm | N/A 2034-01-01 | Janux Therapeutics Inc. | JANX | Campbell David Alan President and CEO | 356,500 | $0 | 356,500 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-03 4:47 pm | N/A 2034-01-01 | Janux Therapeutics Inc. | JANX | DiRaimondo Thomas Chief Scientific Officer | 147,000 | $0 | 147,000 (Direct) | View |